CN116963735A - 奥匹卡朋与左旋多巴组合治疗帕金森病相关的疼痛 - Google Patents

奥匹卡朋与左旋多巴组合治疗帕金森病相关的疼痛 Download PDF

Info

Publication number
CN116963735A
CN116963735A CN202180095156.0A CN202180095156A CN116963735A CN 116963735 A CN116963735 A CN 116963735A CN 202180095156 A CN202180095156 A CN 202180095156A CN 116963735 A CN116963735 A CN 116963735A
Authority
CN
China
Prior art keywords
combination
score
patient
pain
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180095156.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·索阿莱斯达希尔瓦
J·F·达科斯塔德品霍洛查
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Publication of CN116963735A publication Critical patent/CN116963735A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180095156.0A 2021-01-20 2021-08-04 奥匹卡朋与左旋多巴组合治疗帕金森病相关的疼痛 Pending CN116963735A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/PT2021/050001 WO2022158991A1 (en) 2021-01-20 2021-01-20 Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa
PTPCT/PT2021/050001 2021-01-20
PCT/PT2021/050026 WO2022158992A1 (en) 2021-01-20 2021-08-04 Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa

Publications (1)

Publication Number Publication Date
CN116963735A true CN116963735A (zh) 2023-10-27

Family

ID=74494985

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180095156.0A Pending CN116963735A (zh) 2021-01-20 2021-08-04 奥匹卡朋与左旋多巴组合治疗帕金森病相关的疼痛

Country Status (5)

Country Link
US (1) US20240066015A1 (https=)
EP (1) EP4281071A1 (https=)
JP (1) JP2024527175A (https=)
CN (1) CN116963735A (https=)
WO (2) WO2022158991A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860603A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
EP4360627A1 (fr) * 2022-10-26 2024-05-01 Institut National de la Santé et de la Recherche Médicale (INSERM) Traitement de l'arthrose par des inhibiteurs de comt

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20000635A0 (fi) * 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
JP5435165B2 (ja) * 2012-05-31 2014-03-05 小野薬品工業株式会社 医薬用途
PT3782617T (pt) * 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
JP2018500300A (ja) * 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
MX383906B (es) * 2015-10-09 2025-03-14 Teva Pharmaceuticals Int Gmbh Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson
JP2024500754A (ja) * 2020-12-17 2024-01-10 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 早期特発性パーキンソン病のための治療レジメン

Also Published As

Publication number Publication date
WO2022158991A1 (en) 2022-07-28
WO2022158992A1 (en) 2022-07-28
JP2024527175A (ja) 2024-07-22
US20240066015A1 (en) 2024-02-29
EP4281071A1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
Morselli et al. Sleep and metabolic function
MacFarlane et al. Hypnotics in insomnia: the experience of zolpidem
Sprenger et al. Management of motor and non-motor symptoms in Parkinson’s disease
Csoti et al. Parkinson’s disease between internal medicine and neurology
AU2022221450B2 (en) Methods of treating Rett syndrome using fenfluramine
Plodkowski et al. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity
Fabbri et al. Adjunctive therapies in Parkinson’s disease: how to choose the best treatment strategy approach
Stacy et al. Apomorphine for the acute treatment of “off” episodes in Parkinson's disease
Simms et al. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease
TW201424729A (zh) 用於治療創傷後壓力症候群之方法
Inoue et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: a polysomnographic randomized, double-blind, placebo-controlled study
CN116963735A (zh) 奥匹卡朋与左旋多巴组合治疗帕金森病相关的疼痛
JPH09510960A (ja) プロラクチンモジュレータ及びダイエットを利用して肥満を治療する方法
Faulkner Use of α2δ ligands for restless legs syndrome/Willis Ekbom disease
Koeglsperger et al. Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations
Oertel et al. Late (complicated) Parkinson’s disease
Kataoka et al. Early-morning OFF in Parkinson’s disease: A systematic literature review and current therapeutics
Harada et al. Clinical features of malignant syndrome in Parkinson's disease and related neurological disorders
Oertel et al. Early (uncomplicated) Parkinson’s disease
Ferreira et al. Opicapone as an add-on to levodopa in patients with Parkinson’s disease without motor fluctuations: rationale and design of the phase III, double-blind, randomised, placebo-controlled EPSILON trial
van Laar et al. The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine
Stocchi et al. L‐Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard‐Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study
Bloomer et al. Dietary supplement increases plasma norepinephrine, lipolysis, and metabolic rate in resistance trained men
Picillo et al. Medical Management of Movement
Takahashi et al. Daytime symptoms of restless legs syndrome–clinical characteristics and rotigotine effectiveness

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination